Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sobi, Inc.
Subjects will receive oral avatrombopag once daily for 5 days beginning on Day 1, followed by a wait period prior to the procedure, which will occur on Day 10 to 13. The Follow-up Period will include 2 visits; 7 days post-procedure and 30 days after last dose.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women greater than or equal to 18 years of age;
A mean baseline platelet count between:
* 50 × 10\^9/L and \<100 × 10\^9/L for non-chronic liver disease participants
* 50 × 10\^9/L and \<75 × 10\^9/L for participants with chronic liver disease;
Participant is scheduled to undergo operations to critical sites (eg, eye surgery, neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the Investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding
You may not be if
Participant with a history of arterial or venous thrombosis within 6 months of baseline;
Participant with known portal vein blood flow velocity rate \<10 cm/second or previous portal vein thrombosis within 6 months of baseline;
Participant plans to have a platelet transfusion or plans to receive blood products containing platelets within 7 days of the Baseline Visit;
Use of erythropoietin-stimulating agents;
Participant has a known medical history of genetic prothrombotic syndromes; or
Participant has abnormal hemoglobin levels or prothrombin time/international normalized ratio
Clareo Health | Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
